EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSXETG00000033652
Gene Symbol: GUCY1A1
2 Enzyme and pathways 5 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSXETG00000022399
Gene Symbol: GUCY1B1
2 Enzyme and pathways 5 View Cross-references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1, Soluble, Alpha 2

Ensembl ID : ENSXETG00000018493
Gene Symbol: GUCY1A2
2 Enzyme and pathways 5 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein 90kda Alpha Family Class A Member 1

Ensembl ID : ENSXETG00000035813
Gene Symbol: HSP90AA1.1
50 Enzyme and pathways 5 View Cross-references
347 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein 90kda Alpha Family Class B Member 1

Ensembl ID : ENSXETG00000010896
Gene Symbol: HSP90AB1
35 Enzyme and pathways 5 View Cross-references
339 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

High Mobility Group Box 1

Ensembl ID : ENSXETG00000019166
Gene Symbol: HMGB1
34 Enzyme and pathways 5 View Cross-references
582 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H1

Ensembl ID : ENSXETG00000007717
Gene Symbol: HRH1
8 Enzyme and pathways 5 View Cross-references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H2

Ensembl ID : ENSXETG00000029997
Gene Symbol: HRH2
8 Enzyme and pathways 5 View Cross-references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 1

Ensembl ID : ENSXETG00000005253
Gene Symbol: HDAC1
42 Enzyme and pathways 5 View Cross-references
308 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 10

Ensembl ID : ENSXETG00000031474
Gene Symbol: HDAC10
7 Enzyme and pathways 5 View Cross-references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 11

Ensembl ID : ENSXETG00000049324
Gene Symbol: HDAC11
4 Enzyme and pathways 4 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 2

Ensembl ID : ENSXETG00000007339
Gene Symbol: HDAC2
25 Enzyme and pathways 5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).